Intelligent Ultrasound Share Discussion Threads

[chester9] 01/5/2024 18:13

https://www.youtube.com/live/kT7ZA6GPhyA?si=G42HxhhQhK7LzP-vGraham Neary gives a really balanced view 37m 40 secs.

[eeza] 01/5/2024 17:44

Triple bottom on chart.

[40 fathoms] 01/5/2024 12:42

They have just said on the webcast that even if they were to hit the bottom of their 14m to 17m forecast revenue range they will be profitable and cashflow positive this year.

Honestly there is really very little more they can do, the team here is among the very best on AIM.

[masarap] 01/5/2024 10:52

On my watch list and a good company with some excellent research on here.

The 'but' is they are expressing uncertainty on whether they will need a bit more cash cash imo. Their realistic assessment is a good sign of management being open and honest. Funding for small caps can be tough but I don't think there would be a big discount from here if funds are needed but in these markets sometimes waiting for such potential developments can be the best course.

"The UK market is experiencing tougher trading conditions due to the current reduction in NHS capital expenditure spending but anticipate growing revenue from high margin AI-related products and non-UK related simulation markets

Implemented tight control on overheads to offset any softness in UK revenue"

It's not a given they will have to raise as they have a bit of wriggle room with the HSBC facility but I think from recollection from the broker note they anticipated having £2.5m cash but will have about £2m year end. A funding around these levels wouldn't necessarily be a bad thing if it was of sufficient size to accelerate product development.

[40 fathoms] 01/5/2024 09:26

@bmcollins

We are in complete agreement. I am not complaining just buying ... meat and poison and all of that.

[eeza] 01/5/2024 09:22

Words like "difficult UK market conditions" guaranteed to result in 10% drop.

The rest was a cut-and-paste from Jan TU.

[bmcollins] 01/5/2024 09:14

@40 Fathoms
At the risk of "talking my own book", as a shareholer of a reasonable size I do utterly agree with you, to me this statement merely underlined the notes that you have made on this board;

Did we expect a profit this announcement, of course not
Were we expecting cash burn, of course we were but surely going to be covered by HSBC arrangement
Are we happy with revenue increases, absolutely.
L could go on but I'll spare you that !

What this tells me is to get plenty of popcorn and sit & watch the revenues rise via GEHC and as dawn follows dusk we will soon enough see the results

[40 fathoms] 01/5/2024 08:56

Can't say I understand the share price reaction today.

There was nothing new or unexpected in the results. The new HSBC facility provides flexibility in downside scenarios beyond that are beyond the boards various forecast scenarios.

Even if you were to assign todays moves to the poor GEHC results last night, in their earnings call they signalled their strong outlook for ultrasound and Voluson in to the second half.

[chillpill] 01/5/2024 08:38

I have just read the Cavendish note.

All it says to me is we are about to raise £3-5m to give them a cash buffer.

This sums up the AIM market and its failings. Long term shareholders don’t get rewarded for the risk they take.

This is a really great AIM technology company. Btw not a shareholder.

[chester9] 01/5/2024 07:41

Given statement then they are at least 1 year from PBT. With market moving well there are better returns elsewhere for now. Labour winning the election should be good for health shares, date TBC

[joseph moran] 01/5/2024 07:22

The 26091 was a buy at 0765

[chester9] 01/5/2024 07:04

Not a lot of new informationPost year end:· GE HealthCare's SonoLyst software launched as a standard feature on the new Voluson Signature 20 and as an option on the Voluson Signature 18 range of women's health ultrasound machines· ScanNav FetalCheck announced to be used in the largest ever trial on the use of aspirin to prevent pre-eclampsia, funded by the Bill and Melinda Gates Foundation Outlook:· The UK market is experiencing tougher trading conditions due to the current reduction in NHS capital expenditure spending but anticipate growing revenue from high margin AI-related products and non-UK related simulation markets· Implemented tight control on overheads to offset any softness in UK revenue· The business continues to expect revenue in 2024 to be between £14m to £17m and continues to forecast that it will reach profitability with its current cash resources Commenting on the results, Riccardo Pigliucci, Chairman of Intelligent Ultrasound said: "2023 has been another year of important progress for the Group, as we commercialize our regulatory-approved clinical AI software products and develop the next generation of diagnostic AI software. We achieved our number one target for the year, which was to grow AI-related sales to £2m. In addition, our relationship with GE HealthCare continued to develop positively with the launch of SonoLystlive, powered by our obstetrics AI software, on the Voluson Expert ultrasound machine range and post-year end on the Signature ultrasound range. In Q4 2023, we announced the first trials in Africa that will be using our ScanNav FetalCheck AI software to enable an unskilled user to automatically obtain the gestational age of a fetus. With a growing range of AI related products, we remain excited about the future of the business, in this growing market."

[chester9] 30/4/2024 22:46

Let's hope they as promised don't need cash

[eeza] 30/4/2024 17:20

Finals tomorrow.

[chester9] 25/4/2024 07:32

Ok confidence must be low on cash with recent share price movements. Results due next Wednesday. Looking forward to update on progress.

[bamboo2] 22/4/2024 07:48

40F, thank you for sharing your research.

[40 fathoms] 22/4/2024 06:17

Just as a follow up, I think this possible requirement of the DoD and their need for field deployable ultrasound might also account for the fact that NeedleTrainer 2 with the V Scan wireless ultrasound device was launched only 9 months after the first needle trainer.

[40 fathoms] 22/4/2024 05:51

Page 276 item 10 and page 277 item 10a (actual page number not page number on document)

Another puzzle piece towards a possible US DoD order for needle trainer ?

The field portable military ruggedised version that we have recently unveiled would seem to fit the bill nicely here. Whatever system they use I suspect they will not just be ordering one to share ! If they choose us I also suspect you will also see SCANNAV PNB included as part of the order for 6,000 Field Portable Ultrasound units they are looking to buy over the next 5 years (see page 376 - FY 2024 Plans)

Just for clarity USUHS stands for the Uniformed Services University of the Health Sciences and VA stands for Veteran Affairs

[40 fathoms] 19/4/2024 09:26

Cavendish have put out a flash note, no change in target price, I assume if that is coming it will come with the release of the final results.

They state that with the expansion of Sonolystlive to the Voluson Signature 20 that they expect the number of machines on which they will now receive a royalty to be @10,000 per year to that you can add more revenue when it is selected as an optional upgrade on the Swift and Signature 18. They also make the point that there is more to come with the roll out and also other features and product enhancements.

It would now appear that of the @15,000 Voluson machines sold per year we are a standard option on @ 10,000 and available as an option on @3,000.

[eeza] 19/4/2024 06:39

Will it open at 9p offer.

[40 fathoms] 19/4/2024 06:26

Fantastic!

With this news and the additional significant high quality, multi year royalty revenue that it brings, we have turned the corner as a company. This should be confirmed by the results presentation but we can now start to focus on valuation as much as catalysts.

With the significant growth runway ahead of us and given we are tipping in to profitability, 2x this years revenue seems very, very undervalued.

[bmcollins] 19/4/2024 06:09

bamboo & 40fathoms

Thank you both for your frequent posts, todays rns shows how accurate you have both been.
So now we can look forward to 1st of May for the results & what should be a very interesting presentation.

[bamboo2] 19/4/2024 06:07

Notice of results

Analyst and investor briefing



Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces it will issue its audited final results for the year ended 31 December 2023 on Wednesday, 1 May 2024.



A briefing for analysts will be held via Teams on 1 May 2024 at 9.30am. To register, please contact [e-mail]



The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 1 May at 1pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.



Investors can sign up to Investor Meet Company for free and add to meet the Company via:



Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

[bamboo2] 19/4/2024 06:05

SonoLyst, powered by Intelligent Ultrasound's ScanNav AI, launches on new GE HealthCare Voluson Signature Series ultrasound machines





Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces that GE HealthCare's SonoLyst software, powered by Intelligent Ultrasound's ScanNav AI, has been launched on the new Voluson Signature Series portfolio of ultrasound machines, the Signature 20 and Signature 18.



SonoLystlive enhances ultrasound image recognition by automatically capturing images in real-time, as the clinician scans a mid-trimester patient. Using practice guidelines from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the AI software automatically recognises the anatomy, captures the image and checks it off the list of required views. By minimising the need to manually freeze, annotate and store images, the software reduces keystrokes by up to 65% and exam time by up to 40% for sonographers.



SonoLystlive will be offered as a standard feature on the Voluson Signature 20 and as an option on the Voluson Signature 18.



Stuart Gall, CEO of Intelligent Ultrasound, commented: "We are pleased that with this launch, SonoLyst, powered by our ScanNav AI software, is now available on three GE HealthCare ultrasound machine ranges -- Expert, Signature and SWIFT. GE HealthCare is leading the way in using AI software to improve obstetric workflows for the benefit of clinicians and patients, while saving scanning time and destressing the scanning environment for sonographers. We remain excited that our novel 'classroom-to-clinic' approach is making clinical diagnostic ultrasound easier to learn and simpler to use."

[bamboo2] 18/4/2024 18:59

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

*Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and tailor precision care for women

*Latest Voluson Signature ultrasound technology offers an intuitive and ergonomic design allowing clinicians to focus on patient care

April 18, 2024 10:32 AM Eastern Daylight Time

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health. These latest systems combine high-performance hardware with flexible scalable software to help increase clinicians’ confidence in their diagnostic and treatment determinations... [c'ntd]